Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 2 of 26
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
M.D. Anderson Cancer Center
NCT05667532
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
Mayo Clinic
NCT04703244
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Relay Therapeutics
NCT05216432
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
University of Colorado, Denver
NCT03995082
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Memorial Sloan Kettering Cancer Center
NCT05561842
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Tempus AI
NCT07211178
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
University of Chicago
NCT04541381
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
Memorial Sloan Kettering Cancer Center
NCT06780176
The Immune System's Response to Young Women's Breast Cancer
University of Colorado, Denver
NCT01503190
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT07076485
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Greenwich LifeSciences
NCT05232916
Factors Associated With Breast Cancer Risks and Outcomes
Memorial Sloan Kettering Cancer Center
NCT07294703
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Cancer Institute (NCI)
NCT00451022
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT05768139
A Study of Language Interpretation Solutions for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06721065
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity
NCT06757634
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Rocky Mountain Cancer Centers
NCT01185132
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Icahn School of Medicine at Mount Sinai
NCT05146297
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
AstraZeneca
NCT06103864
Comprehensive Outcomes for After Cancer Health
Pack Health
NCT05349227
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Memorial Sloan Kettering Cancer Center
NCT00823654
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT02732171
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
University of Illinois at Chicago
NCT05483283
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
University of Hawaii
NCT05369546
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
University of Arizona
NCT03954431
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
Memorial Sloan Kettering Cancer Center
NCT03572374
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Relay Therapeutics
NCT06982521
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals
NCT06016738
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
UNC Lineberger Comprehensive Cancer Center
NCT03769415
Magnetic Resonance Imaging of Breast Cancer
Stanford University
NCT01035112
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
UNC Lineberger Comprehensive Cancer Center
NCT06896162
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Uppsala University
NCT04722692
Evaluation of the Bexa Breast Examination
Sure
NCT06643767
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Dana-Farber Cancer Institute
NCT04893109
Intra-Operative Radiation Registry
Albert Einstein College of Medicine
NCT04994067
Together After Cancer
University of South Florida
NCT05645471
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Memorial Sloan Kettering Cancer Center
NCT01788839
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Guardant Health
NCT05935384
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune
NCT05983432
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
NCT05123482
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
Northwestern University
NCT05703178
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche
NCT06790693
Cardiometabolic Screening Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05386719
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04751435
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Stemline Therapeutics
NCT05563220
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
University of Oklahoma
NCT07014618
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06618287
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
Washington University School of Medicine
NCT06981208
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation
NCT06072612
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.